Pu. Huguenin et al., Quality of life in patients cured from a carcinoma of the head and neck byradiotherapy: The importance of the target volume, INT J RAD O, 45(1), 1999, pp. 47-52
Citations number
10
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Purpose: To assess the health-related quality of life (QOL) of long-term su
rvivors of carcinomas of different subsites of the head and neck following
curative radiotherapy (RT),
Patients and Methods: Patients continuously free from recurrence or second
primary tumors treated 1988-1994 were contacted 5.1 to 5.9 years after RT a
nd asked to fill in the EORTC QLQ-C30 core questionnaire and the H&N cancer
module, RT had been restricted to the glottis (group A; carcinomas of the
vocal cord T1-2 NO), or had included bilateral neck nodes and the primary t
umor outside the nasophargnx (group B; AJC Stage II to IV) or within the na
sopharynx, respectively (group C; Stage II to IV). Response rate was 97% (g
roup ri; ii = 41), 69% (group B; n = 26) and 71% (group C; n 12), respectiv
ely. The groups were different with respect to age (older in group A), alco
hol consumption (absent in group C) and proportion of females (more in grou
p C),
Results: Patients with nasopharyngeal cancer reported the highest morbidity
on the H&N module (dry mouth, sticky saliva, trismus. problems with teeth,
trouble eating). However, these symptoms did not have a high impact on glo
bal QOL or fuction scores on the QLQ-C30 core questionnaire, Patients in gr
oup B reported a lower global QOL but less severe symptoms on the module.
Conclusion: The high morbidity of patients treated for a nasopharyngeal can
cer may be explained by the location of the target volume which included th
e bilateral temporo-mandibular joints and the salivary glands. These patien
ts require appropriate care during follow-up and will probably profit most
from new RT techniques with sparing of normal tissues. (C) 1999 Elsevier Sc
ience Inc.